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Abstract
Background: Hypertrophic cardiomyopathy is a genetic autosomal dominant disease characterized by left ventricular
hypertrophy. The molecular diagnosis is important but still expensive. This work aimed to find clinical predictors of a
positive genetic test in a Brazilian tertiary centre cohort of index cases with HCM.
Methods: In the study were included patients with HCM clinical diagnosis. For genotype x phenotype comparison we
have evaluated echocardiographic, electrocardiographic, and nuclear magnetic resonance measures. All patients
answered a questionnaire about familial history of HCM and/or sudden death. β-myosin heavy chain, myosin
binding protein C, and troponin T genes were sequenced for genetic diagnosis.
Results: The variables related to a higher probability of a positive genetic test were familial history of HCM, higher
mean heart frequency, presence of NSVT and lower age. Probabilities of having a positive molecular genetic test were
calculated from the final multivariate logistic regression model and were used to identify those with a higher
probability of a positive molecular diagnosis.
Conclusions: We developed an easy and fast screening method that takes into account only clinical data that
can help to select the patients with a high probability of positive genetic results from molecular sequencing of
Brazilian HCM patients.
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Background
Hypertrophic cardiomyopathy (HCM) is a genetic auto-
somal dominant disease characterized by left ventricular
(LV) hypertrophy, without dilatation, usually asymmetric
and mainly septal in the absence of any other cardiac or
systemic disease that can lead to secondary hypertrophy
[1,2]. The main symptoms, when present, are dyspnea
on exercise, angina, heart palpitations, pre-syncope or
syncope, but many patients may remain asymptomatic
and some may have sudden death (SD) as the first mani-
festation of the disease. The estimated prevalence is 0.2%
(1:500), corresponding to 0.5% of all cardiomyopathies [3].
The disease is caused by a mutation in sarcomere,
disc-Z, or calcium handling genes. So far, over 20 genes
have been associated with the disease, and over 1,000
different mutations have been described. However, the
most common genes causing the disease are β-myosin
heavy chain (MYH7), myosin binding protein C (MYBPC3),
and troponin T (TNNT2) [4].
Molecular diagnosis is very important for several rea-
sons. When the clinical diagnosis is a certainty, establish-
ment of the molecular defect is a diagnostic confirmation,
because HCM is a genetic disease. On the other hand, a
genetic diagnosis can help in uncertain cases, such as
when this is little hypertrophy, hypertrophy in athletes, or
hypertensive patients are being screened [2]. In addition,
genetic diagnosis allows the identification of children and
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adults with subclinical manifestations of the disease,
especially in the familial context.
Although genetic testing is important, and it is recom-
mended by the European Cardiology Society, it is not
yet a reality in most clinical settings, mainly due to its
high cost and the lack of well-established genotypic and
phenotypic correlations. Some authors previously reported
the use of clinical features to predict a positive genetic
test [5,6], as this can help to optimize genetic testing by
prioritizing patients with a high chance of a positive
genetic test.
Thus, this work aimed to find clinical predictors of a
positive genetic test in a Brazilian tertiary centre cohort
of index cases with HCM.
Methods
Patients
All the subjects included in the study are HCM index
patients clinically diagnosed by expert cardiologists. All
of them are patients treated in the respective hospitals
the researchers are affiliated and were invited to partici-
pate of the research during the periodic consultation.
The assistant physician explained about the research
and referred them to the Molecular genetics Analysis
Laboratory. A septum thickness above 15 mm in the
absence of any other disease that could lead to secondary
hypertrophy was the criterion used. It included patients
from the Heart Institute, a tertiary centre at the University
of São Paulo Medical School, but also patients from
other cities in Brazil, namely Vitória, Manaus, and Recife.
All participants signed the informed consent, and the
University of São Paulo Hospital’s Research Ethics
Committee (CAPPesq) approved the project. Only one
patient per family was included in the present analysis.
Examinations
For genotype x phenotype comparison, clinical data were
obtained from the patients’ medical records. We have
evaluated echocardiographic, electrocardiographic, and
nuclear magnetic resonance measures, when available.
All patients answered a questionnaire about familial his-
tory of HCM and sudden death. The presence of a famil-
ial history was divided in three categories: absent, when
there was no history, present, when at least one relative
had a confirmed diagnosis for HCM and unsure, when
the patient mentions that there is a history of cardiac
disease in the family but without an established HCM
diagnosis.
Electrocardiography
Tracings were analysed for the presence or absence of
atrial fibrillation, LV hypertrophy, left bundle branch
block, left atrial enlargement, delta waves and abnormal
Q waves.
Ambulatory ECG monitoring
Tracings were recorded with 3 bipolar leads for 24 hours
using commercially available equipment and analysed by
an experienced reader. Complex ventricular arrhythmia
was defined as the presence of non-sustained ventricular
tachycardia (NSVT) defined as >3 consecutive ventricular
ectopic complexes occurring at a rate of >100 beats/min.
Echocardiography
Two-dimensional echocardiography with M-mode re-
cording was obtained following the recommendations of
the American Society of Echocardiography (ASE) [7]. The
resting systolic gradients were measured with colour-
guided continuous-wave Doppler (CWD) across LV cavity
and outflow tract, avoiding the effect of mitral regurgi-
tation when present. The examinations were performed
using standard equipment with 2.5 and 3.5 MHz
transducers.
Genetic testing
The polymerase chain reaction (PCR) was performed
from DNA using primers that cover the entire coding
region from β-myosin heavy chain (MYH7), myosin
binding protein C (MYBPC3), and troponin T (TNNT2)
genes (primer sequences available upon request). After
PCR, the fragments were purified with the ExoSAP-IT®
enzyme (GE Healthcare). The sequencing reaction was
performed with BigDye Terminator V3.1 Cycle sequen-
cing Kit® (Life Technologies) and EDTA/ethanol precipi-
tation protocol. The samples were sequenced in an
automatic sequencer ABI3500xl (Life Technologies).
The sequences were evaluated with the SeqMan
program (DNASTAR Lasergene, Madison, WI) and
compared with the reference sequence in the NCBI
database. For MYH7, MYBPC3, and TNNT2, the refer-
ences were, respectively, NM_000257.2, NM_000256.3,
and NM_000364.2 [8]. When an undescribed mutation
was found, we used bioinformatics algorithms to evaluate
the pathogenic potential of the alteration. The SIFT [9]
and Polyphen [10] programs were used only for substitu-
tions, and the MutationTaster [11] was used to analyze
deletions, insertions, and intron alterations. A mutation
was labeled as pathogenic if (1) it had been previously de-
scribed as causing disease; (2) it generated an aminoacid
change and was considered pathogenic by all 3 programs
above or in 2 programs but the aminoacid was conserved.
Statistical analysis
Statistical analyses were performed with the SPSS pro-
gram 15.0. The ANOVA test was used to compare
means, Fisher’s exact test for frequencies comparison,
and uni- and multivariate logistic regression for con-
structing the prediction model. The variables with a
statistical difference in the ANOVA test were tested in
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the univariate logistic regression and independent vari-
ables with a p value < 0.1 were included in the multivari-
ate logistic regression. We did not use any hierarchical
or stepwise approach in the multivariate logistic regres-
sion model.
Accuracy of the final prediction model was explored
through ROC analysis. Sensitivity, specificity, positive
and negative predictive values according to model cut
offs were determined. The prediction model was gener-
ated with the probability of a positive genetic test derived
from the regression model (where (β) are the regression
coefficients of variables in the final model). These prob-
abilities were imputed in a ROC analysis and a cut-off
maximizing specificity and sensitivity was chosen.
p ¼ e
β0þβ1x
1þ eβ0þβ1x
Results
This study analysed 268 patients, 58% males and 42%
females with a median age of 46 years (SD = 15.6). The
youngest was 13 years old and the oldest 90. We ob-
tained the data from ECG and echocardiogram from all
the patients and data from holter and resonance were
obtained respectively from 176 and 116 patients. The
variable used for the analysis were obtained as followed:
presence or absence of atrial fibrillation, obtained from
ECG, septal and posterior wall thickness, left atrium size
and ejection fraction, obtained from echocardiogram,
medium heart rate and presence of NSVT from Holter and
presence or absence of fibrosis from cardiac resonance.
The median septal thickness was 20 mm (SD = 6),
posterior wall thickness (PW) was 12 mm (SD = 5), left
atrium size (LA) was 42 mm (SD = 8), and ejection frac-
tion (EF) was 71% (SD = 9). There were no statistical
differences in these criteria regarding sex.
Among the patients, we found a pathogenic mutation
in 131 of them (48.8%). Seventy-eight (59.5%) of the
mutations were in the MYH7 gene, 50 (38.2%) in the
MYBPC3 gene, and 3 (2.3%) in the TNNT2 gene. All
variant used for this analysis were considered pathogenic
according to our criteria described on Methods section.
The full variant list can be found a previous article from
our group [12]. The comparison between clinical fea-
tures and presence or absence of an identified mutation
has shown that patients with a mutation are, on average,
younger in age, younger in age at diagnosis, have higher
average cardiac frequency, and higher frequency of
patients with NSVT (Table 1).
Familial history of HCM was also correlated with the
presence or absence of an identified mutation (Table 2),
and it was found that when there is a proven familial
history, the chance of finding a mutation is significantly
higher than when there is no familial history. When the
familial history was unsure, as in the cases when the
Table 1 Clinical features with absence or presence of a mutation in one of the studied genes
Mutation
Absence Presence
Mean SD Mean SD p value
Age at diagnosis (years) 38 16 33 13 0.026
Current age (years) 48 17 43 13 0.028
MCF (bpm) 67 9 71 11 0.006
Septum (mm) 20 6 21 5 0.179
PW (mm) 12 3 12 6 0.581
LA (mm) 42 8 43 8 0.164
EF (%) 71 9 71 9 0.638
Count Frequency (%) Count Frequency (%)
Sex M 79 57.2 76 58.3 0.902
F 59 42.8 54 58.5
AF No 91 93.8 90 87.4 0.150
Yes 6 6.2 13 12.6
Obstructive No 73 64.6 81 70.4 0.397
Yes 40 54.1 34 29.6
NSVT No 63 75.9 50 54.9 0.004
Yes 20 24.1 41 45.1
SD Standard deviation, MCF medium cardiac frequency, PW posterior wall thickness, LA left atrium size, EF ejection fraction, AF atrial fibrillation, obstructive
ventricular gradient above 30 mmHg, NSVT non-sustained ventricular tachycardia. p-values < 0.05 are marked in bold.
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patient mentioned relatives with cardiac disease, but
without a clinical diagnosis of HCM, the odds of identi-
fying a mutation were higher than in those with a
negative family history and statistical similarity to those
with a confirmed familial history.
The variables with a statistical difference in the ANOVA
test were tested in the univariate logistic regression and
independent variables with a p value < 0.05 were included
in the multivariate logistic regression: familial history of
HCM, average heart frequency, NSTV and age (Table 3).
Probabilities of having a positive molecular genetic test
were calculated from the final multivariate logistic regres-
sion model and were used to identify those with a higher
probability of a positive molecular diagnosis. The pre-
dicted probabilities distribution and ROC curve are shown
respectively in Figures 1 and 2. The AUC is 0.775 and 0.55
was used as the cut-off value for the ROC curve.
Discussion
Genetic test positivity prediction model
The genetic test positivity prediction model developed in
this study is useful to analyse a priori a patient’s chance
of finding a mutation when ordering genetic testing. In
the clinical practice scenario, cardiologists can give a
more accurate estimate to patients regarding the mo-
lecular test. In the large scale screening scenario, such as
in national cascade screening projects, only patients with
a greater chance of having a positive genetic test would
be analysed, which could optimize the use of reagents
and analysis time. This model is particularly important
in centres with fewer resources, because the genetic test
is still very expensive. Especially in the Brazilian scenario,
where few academic centres have the structure and budget
to perform the test, this method can serve as a cost-
effective tool. Our main focus with this model is the cas-
cade screening. Patients with borderline hypertrophy or
with uncertain diagnosis were not included in this study,
so such predictor may not be accurate for this group.
The sensitivity and specificity values can be adjusted
according to a particular interest. For example, if one
wants to maximize the number of positive patients in-
cluded, the sensitivity and specificity can be modulated
by changing cut-off values. In the simulations for the
studied population, adjusting the predicted probability
cutoff for 0.34, which represents an approximate 90%
sensitivity, from the 122 included in the analysis, 91
would be tested. Of those, 60 patients would be positive.
From the 31 patients not tested, only 7 would have a
positive result, so we would not be testing 24 patients
predicted as negative. These savings, in a national
screening program, can signify an important economic
resource.
To applied this model, one can use the values from
Table 3 to calculate the predicted probability of a posi-
tive genetic test. P is equal the predicted probability, βo
is the constant value, β1 is the variable constant and x is
the variable value if continuous or 0 and 1 if the variable
is categorical.
In this work, we are using predicted probability, thus
what we can conclude is regarding higher or lower prob-
abilities, not certainties. For example, we saw in the lo-
gistic regression model that each patient’s year addition
Table 2 Comparison of positive, negative and unsure HC familiar history and mutation identification
HC familial history
Absent Present Unsure
Count Frequency Count Frequency Count Frequency
Mutation Absent 16 69.6% 23 37.1% 33 50%
Present 7 30.4% 35 62.9% 33 50%
Table 3 Variables included in the multivariate logistic regression
B S.E. Wald df Sig. Exp(B) 95.0% C.I. for EXP(B)
Lower Upper
HCFH 7.222 2 0.027
HCFH (1) 1.767 0.661 7.152 1 0.007 5.856 1.603 21.387
HCFH (2) 1.261 0.665 3.594 1 0.058 3.53 0.958 13.004
AHF 0.044 0.021 4.471 1 0.034 1.045 1.003 1.089
NSVT 1.603 0.479 11.193 1 0.001 4.969 1.943 12.709
Age −0.053 0.018 9.211 1 0.002 0.948 0.916 0.981
Constant −2.507 1.718 2.13 1 0.144 0.081
HCFH Familial history of HC, HCFH (1) familial history of cardiac disease with confirmed HC diagnosis, HCFH (2) familial history of cardiac disease without HC
diagnosis, AHF average heart frequency, NSVT non-sustained ventricular tachycardia.
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decreases the chance of finding a mutation in the gen-
etic test. We did not define a cutoff for this measure,
meaning that one can find the mutation in any age, but
the older the patient is, the lower is the probability of
finding a mutation. On the other hand, the presence of a
confirmed HCM family history increases the chance of
finding a mutation almost 6 times when compared to
patients who don’t have a positive HCM family history.
Ingles et al. [5] also used this approach to identify
positivity predictors for genetic testing in an Australian
HCM population. The multivariate analysis of this popu-
lation identified female sex, LV thickness, HCM familial
history, and SD familial history as associated with a
higher chance of mutation identification. The authors
considered familial history as a key predictor of a posi-
tive genetic test in their population, with a 3 times
higher chance of a positive result compared to patients
without a familial history, which was similar to what we
found in this study. In their study, this detection rate
was even higher when the patient also had an SD familial
history. Differently from what was found in this study, age
at diagnosis was not significant in the Australian popula-
tion, although the p value was 0.052.
Another study performed by Gruner et al. [6] in a
Toronto HCM population showed that in these patients
age at diagnosis, female sex, HCM familial history, and
SD familial history were also correlated with a higher
probability of a mutation identification. In addition, the
study correlated hypertension and dyslipidaemia as nega-
tive predictive factors, with a higher frequency of both in
genetically negative patients. Other strong predictors iden-
tified were morphology subtype, as previously described
[13] and maximal wall LV thickness and LW thickness.
The identification of NSVT as one of the predictors
for a positive genetic test is a very interesting observa-
tion, since this is one risk factor for sudden death in
HCM patients. In a previous work, Olivotto et al. [14]
Figure 1 Predicted probability distribution.
Figure 2 ROC curve for the developed model.
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compared patients with and without an identified sarco-
meric mutation and found that there was a difference
regarding those, with patients with a positive genetic test
being related to a less favourable clinical outcome, espe-
cially regarding end stage heart failure, but not sudden
death. This finding in our study may show that the pres-
ence of a mutation can indeed be related with a higher
risk of sudden death related risk factors.
Study limitations
The limitations of this study are the lack of patients with
hypertension, since it was an exclusion criterion for
HCM diagnosis in the participating centres; therefore,
we could not test it as a negative predictor. Also, we
only studied the three most important genes (MYH7,
MYBPC3, and TNNT2), thus patients with mutations
in other sarcomeric genes may be wrongly labelled as
mutation negative. But the frequency of these genes in
HCM is very low, so we believe that the lack of these
data does not change the results found.
These finding may be limited to the Brazilian popula-
tion. Replication studies in other populations should be
made to confirm these results.
As new technology becomes available, such as next
generation sequencing screening techniques, this reality
may change and screening programs will have to con-
stantly adapt to new molecular data.
Conclusion
In conclusion, we developed an easy and fast screen-
ing method that takes into account only clinical data
that can help to select the patients with a high prob-
ability of positive genetic results for molecular se-
quencing of Brazilian HCM patients. This method can
be applied in centres with limited resources to save
time and money.
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